Form 4: Fortress Biotech Exits Checkpoint Therapeutics Stake Following $4.10/Share Merger

Fortress Biotech, a significant shareholder and director, has fully divested its holdings in Checkpoint Therapeutics following the company's acquisition by Sun Pharmaceutical Industries for $4.10 per share plus a contingent value right.

Summary

• Fortress Biotech, Inc., a 10% owner and director of Checkpoint Therapeutics, Inc. (CKPT), reported significant changes in its beneficial ownership.
• On May 29, 2025, Fortress Biotech disposed of 100,000 shares of Checkpoint Therapeutics common stock at an exercise price of $1.29 per share. This transaction resulted from the exercise of warrants by Lindsay A. Rosenwald and Michael S. Weiss, which were originally issued from Fortress Biotech's holdings.
• On May 30, 2025, Fortress Biotech disposed of its remaining 6,122,249 shares of common stock and 700,000 shares of Class A Common Stock in Checkpoint Therapeutics.
• This complete disposition was a direct consequence of the merger of Checkpoint Therapeutics with Snoopy Merger Sub, Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc.
• As per the merger agreement, each share of Checkpoint Therapeutics common stock and Class A Common Stock was converted into the right to receive $4.10 in cash, without interest, and one non-tradable contingent value right (CVR) for a potential additional payment of up to $0.70 upon achievement of a specified milestone.
• Following these transactions, Fortress Biotech, Inc. no longer holds any beneficial ownership in Checkpoint Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a merger, which typically provides a clear exit strategy and defined value for shareholders. The inclusion of a CVR offers potential additional upside. For Fortress Biotech, it represents a complete and presumably profitable exit from its investment in Checkpoint Therapeutics, aligning with the terms of a pre-announced acquisition.

Positives

• Fortress Biotech realized cash proceeds of $4.10 per share for its common stock and Class A common stock holdings in Checkpoint Therapeutics as part of the merger.
• The contingent value right (CVR) offers potential for an additional cash payment of up to $0.70 per share upon the achievement of a specified milestone, providing potential upside beyond the initial cash consideration.

Negatives

• Fortress Biotech no longer has any direct or indirect beneficial ownership in Checkpoint Therapeutics, indicating a complete exit from its investment in the company.
• The disposition of 100,000 shares on May 29, 2025, at an exercise price of $1.29, while part of a warrant exercise, represents a sale at a lower price point compared to the subsequent merger consideration of $4.10.

Risks

• The contingent value right (CVR) is non-tradable, limiting liquidity, and the payment of up to $0.70 is contingent upon the achievement of a specified milestone, meaning there is no guarantee of receiving this additional payment.

Future Outlook

NA

Industry Context

This Form 4 filing details the finalization of an acquisition in the biotechnology/pharmaceutical sector, where a smaller company (Checkpoint Therapeutics) is acquired by a larger entity (Sun Pharmaceutical Industries). Such mergers are common in the industry, often driven by the acquiring company's interest in the target's pipeline assets, market position, or intellectual property. The inclusion of a Contingent Value Right (CVR) is a common mechanism in biotech mergers, allowing the acquirer to tie a portion of the purchase price to the successful achievement of specific clinical or regulatory milestones, thereby sharing risk and reward related to pipeline assets.

Comparison to Industry Standards

• The acquisition price of $4.10 per share plus a CVR of up to $0.70 per share for Checkpoint Therapeutics by Sun Pharmaceutical Industries can be compared to other recent biotech acquisitions. For instance, similar deals often involve a premium over the pre-announcement trading price, reflecting the value of the target's assets, particularly its oncology pipeline (e.g., Cosibelimab for Checkpoint).
• The use of a Contingent Value Right (CVR) is a standard practice in biotech M&A, especially when the target company has late-stage clinical assets or regulatory approvals pending. Examples include the acquisition of Array BioPharma by Pfizer, where CVRs were used, or Celgene's acquisition by Bristol-Myers Squibb, which also included CVRs tied to specific drug approvals.
• The valuation implied by the $4.10 cash component, combined with the potential $0.70 CVR, should be assessed against Checkpoint's clinical progress, particularly its lead asset Cosibelimab, and its market capitalization prior to the merger announcement, relative to peer companies with similar pipeline stages and therapeutic areas.

Related Party Transactions

• The exercise of warrants by Lindsay A. Rosenwald and Michael S. Weiss, who received them from Fortress Biotech (a 10% owner and director of Checkpoint Therapeutics), could be considered a related party transaction given their association with Fortress Biotech and the Issuer.

Stakeholder Impact

• Shareholders (Fortress Biotech): Received cash consideration of $4.10 per share and a non-tradable CVR for up to $0.70 per share, representing a complete liquidation of their investment in Checkpoint Therapeutics.
• Shareholders (General): All public shareholders of Checkpoint Therapeutics would have received the same cash and CVR consideration, marking the end of their investment in the publicly traded entity.
• Employees of Checkpoint Therapeutics: The company is now a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc., which may lead to integration efforts and potential changes in operations or personnel structure, though not explicitly stated in this filing.
• Sun Pharmaceutical Industries, Inc.: Successfully acquired Checkpoint Therapeutics, gaining its assets and pipeline, including the potential for the CVR milestone.

Next Steps

• Fortress Biotech will no longer report beneficial ownership in Checkpoint Therapeutics.
• The contingent value right (CVR) holders will await the achievement of the specified milestone for the potential additional payment of up to $0.70 per share.
• Checkpoint Therapeutics will operate as a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc.

Key Dates

Keywords

SEC Form 4, Insider Trading, Beneficial Ownership, Fortress Biotech, Checkpoint Therapeutics, CKPT, Merger, Acquisition, Sun Pharmaceutical Industries, Contingent Value Right, CVR, Stock Disposition, Warrant Exercise